Journal of Pharmacy Technology最新文献

{"title":"Medication Use Among Patients Reporting Xerostomia of an Academic Dental Clinic.","authors":"Michael P Krajewski,&nbsp;QingXiang Mo,&nbsp;Chi-Hua Lu,&nbsp;Albert Cantos,&nbsp;Steve Feuerstein,&nbsp;Michael J Brandt,&nbsp;Robert G Wahler","doi":"10.1177/87551225221108599","DOIUrl":"https://doi.org/10.1177/87551225221108599","url":null,"abstract":"<p><strong>Background: </strong>Global prevalence of xerostomia has been reported at 22% (range 0.01%-45%), negatively impacting oral health, nutrition intake, and quality of life. The causal relationship between xerostomia and medications remains uncertain but greater understanding could guide interventions.</p><p><strong>Objective: </strong>To describe the demographic characteristics and medication regimens in patients with xerostomia of an academic dental clinic.</p><p><strong>Method: </strong>This is a retrospective academic dental clinic record review from July 1, 2018 to October 27, 2020. Patient records were obtained from the University at Buffalo, School of Dental Medicine. Xerostomia status was determined via query of electronic health records and validated by manual review. Pharmacologic class and xerostomic potential of medications were identified by the Veterans Affairs Drug Classification System and drug compendia, respectively. Predictors of medication use were assessed using a multiple logistic regression model.</p><p><strong>Results: </strong>Of 37 403 examined records, 366 (0.98%) were identified as xerostomic. After excluding confounding factors (Sjogren's and radiation), 275 of 317 patients received at least one xerostomic medication, majority were female (240, 66%) versus male (126, 34%). Mean ± (SD) age was 64.9 ± 15.11 years. A total of 208 (57%) patients were aged ≥65. The median number of total and xerostomic medications were 8 (interquartile range [IQR], 4-12) and 4 (IQR, 2-7), respectively. The 3 most prevalent xerostomic pharmacologic classes were antidepressants (131, 35%), gastric medications (101, 28%), and vitamin D (87, 24%).</p><p><strong>Conclusion: </strong>Despite observed prevalence of xerostomia lower than global prevalence, xerostomic medication burden for patients experiencing xerostomia was high. Pharmacist-led interprofessional collaborations should be investigated to reduce xerostomic burden.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420921/pdf/10.1177_87551225221108599.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9781698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Experience With Interleukin-6 Receptor Antagonists in Patients With COVID-19 Admitted to a Community Hospital.","authors":"Kyle Manning, Chris Whitman, Lindsey Hohmann, Jessica Tubbs, Darrell Childress, Jose A Leon de la Rocha","doi":"10.1177/87551225221104323","DOIUrl":"10.1177/87551225221104323","url":null,"abstract":"<p><p><b>Background/objective:</b> The efficacy of interleukin-6 (IL-6) inhibitors in hospitalized patients with severe coronavirus disease 2019 (COVID-19) pneumonitis is unclear. <b>Method:</b> This retrospective, observational cohort study included patients hospitalized at a community hospital with COVID-19 pneumonia from March 2020 to May 2020. All patients were treated with standard of care (SOC), and a nonrandomly selected subset of patients also received an IL-6 inhibitor. The primary outcome was clinical response, defined as an improvement of at least 2 categories relative to baseline on a 7-category ordinal scale up to hospital discharge or 30 days. In adjusted analyses, logistic and linear regression models were conducted, controlling for covariates of hospital length of stay (LOS), intensive care unit (ICU) care, ICU LOS, gender, age, race, and Charlson Comorbidity Index. <b>Results:</b> A total of 133 patients met inclusion criteria. In all, 30 patients received an IL-6 inhibitor plus SOC. There was no statistical difference in clinical outcome between groups as 76.7% in the SOC alone group and 70.0% in the IL-6 inhibitor group met the defined endpoints for clinical response (<i>P</i> = 0.477). In the adjusted analysis, patients treated with IL-6 inhibitors were approximately 4 times more likely to meet the primary endpoint compared with patients with SOC alone (adj. odds ratio = 4.325; <i>P</i> = 0.038, 95% confidence interval = [1.09-17.18]). <b>Conclusions:</b> Compared with SOC alone, IL-6 inhibitors were not associated with a significant clinical response. However, after adjusting for covariates, this study suggests that the initiation of IL-6 inhibitors in patients with early COVID-19 pneumonitis before progression to the ICU may be associated with improved clinical status.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420917/pdf/10.1177_87551225221104323.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9750608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps.","authors":"Renee R Koski,&nbsp;Luke Hill,&nbsp;Kylee Taavola","doi":"10.1177/87551225221105749","DOIUrl":"https://doi.org/10.1177/87551225221105749","url":null,"abstract":"<p><p><b>Objective:</b> To review published literature for biologic treatment of nasal polyps. <b>Data Sources:</b> PubMed search performed on February 16, 2022, using search terms: biologics, benralizumab, dupilumab, mepolizumab, omalizumab, or reslizumab AND nasal polyps, nasal polyposis, or chronic rhinosinusitis with nasal polyposis (CRSwNP). Inclusion criteria were English language, published randomized controlled trials, post hoc analyses, and meta-analyses evaluating biologics for nasal polyposis, with or without comorbid asthma, and no date limits. Additional studies were found through references of primary and tertiary literature. <b>Study Selection and Data Extraction:</b> Nineteen studies, including 8 randomized controlled trials, 2 meta-analyses, and 9 post hoc analyses, examined the efficacy and safety of biologics for nasal polyposis. Agents studied included benralizumab, dupilumab, mepolizumab, omalizumab, and reslizumab. Studies had similar inclusion (refractory and recurrent CRSwNP) and exclusion criteria. All studies included the use of an intranasal corticosteroid (mometasone or fluticasone) in addition to the biologic or placebo. The most commonly studied primary endpoint was change in endoscopic nasal polyp score. <b>Data Synthesis:</b> All studies, post hoc analyses, and meta-analyses found improvement in endoscopic, clinical, and/or radiographic endpoints with benralizumab, dupilumab, mepolizumab, omalizumab, or reslizumab in patients with CRSwNP with or without comorbid asthma. Dupilumab has the most published data. Dupilumab, mepolizumab, and omalizumab are the only biologics currently Food and Drug Administration-approved for CRSwNP. <b>Conclusion:</b> Biologics are beneficial for treating nasal polyps with or without comorbid asthma. The choice depends on patient and provider preference and insurance coverage.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420916/pdf/10.1177_87551225221105749.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9765982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olanzapine/Samidorphan: A New Option for the Treatment of Adults With Schizophrenia or Bipolar I Disorder.","authors":"Huy Pham,&nbsp;Halford Warlick,&nbsp;Ricardo Bermudez,&nbsp;Quan Nguyen,&nbsp;Jose A Rey","doi":"10.1177/87551225221114281","DOIUrl":"https://doi.org/10.1177/87551225221114281","url":null,"abstract":"<p><strong>Objective: </strong>To review the pharmacology, pharmacokinetics, and efficacy and safety data of a combination of olanzapine and samidorphan (OLZ/SAM) for the treatment of schizophrenia and bipolar I disorder, which mitigates the possible unwanted side effects of weight gain associated with olanzapine (OLZ).</p><p><strong>Data sources: </strong>The review was done with a bibliographic survey of studies using MEDLINE/PubMed (January 1999-May 2021) database using the keywords olanzapine and samidorphan. Abstracts, scientific posters, and information from the manufacturer's product labeling were evaluated for inclusion. Inclusion criteria: phase 2, phase 3, and open-labeled studies that evaluated the use of OLZ/SAM for the treatment of schizophrenia and bipolar I disorder.</p><p><strong>Data synthesis: </strong>We have included one phase 2 dose-ranging exploratory study, two phase 3 efficacy and safety studies, and several open-label extension studies without a comparator. For the treatment of schizophrenia, OLZ/SAM and OLZ alone were analyzed in 2 randomized, double-blind comparison studies of approximately 960 patients. Analysis indicated that OLZ (5-20 mg)/SAM (10 mg) significantly mitigated the side effect of weight gain compared with OLZ alone (control) while maintaining antipsychotic efficacy. For bipolar I disorder, OLZ/SAM was approved as an acute treatment for manic or mixed episodes, as well as an adjunct to valproate or lithium for manic/mixed episodes based on bridging strategy allowed by the Food and Drug Administration.</p><p><strong>Relevance to patient care and clinical practice: </strong>The combination of olanzapine and samidorphan demonstrated efficacy for the treatment of schizophrenia with a dosage range of 5 to 20 mg OLZ to a 10-mg fixed dose of samidorphan. Advantages of this drug combination include once-daily dosing, favorable tolerability, and most importantly, mitigation of weight gain, which may encourage adherence, when compared with OLZ alone.</p><p><strong>Conclusion: </strong>The new combination treatment of OLZ/SAM is a unique antipsychotic formulation to provide the recognized efficacious treatment of OLZ, while mitigating the weight gain and possibly the weight-related adverse effects secondary to OLZ monotherapy.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420915/pdf/10.1177_87551225221114281.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9943092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Possible Case of COVID-19 Booster Vaccine-Associated Rhabdomyolysis and Acute Kidney Injury.","authors":"Kendra Unger,&nbsp;Charles D Ponte,&nbsp;Dylan Anderson","doi":"10.1177/87551225221093944","DOIUrl":"https://doi.org/10.1177/87551225221093944","url":null,"abstract":"<p><p><b>Background:</b> Nearly 10 billion doses of the various messenger ribonucleic acid (mRNA) and viral vector vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been administered worldwide. Adverse drug reactions (ADRs) have been overwhelmingly mild to moderate in nature. Rare side effects have included myocarditis/pericarditis, <i>thrombosis with thrombocytopenia syndrome (TTS)</i>, Guillain-Barré Syndrome (GBS), and death. However, vaccine-related ADR data are still being collected using a variety of reporting systems. <b>Purpose:</b> We will describe a case of suspected mRNA coronavirus disease 2019 (COVID-19) booster-related rhabdomyolysis in a woman who developed signs and symptoms 10 days after administration of the vaccine dose. With a Naranjo ADR probability score of 4, the vaccine was deemed to be a possible cause of our patient's rhabdomyolysis. <b>Methods:</b> A search of the VAERS (Vaccine Adverse Event Reporting System) mined in November 2021 revealed 386 reported cases of COVID-19 vaccine-related rhabdomyolysis. However, system limitations make the utility of the information problematic. <b>Conclusions:</b> It is vitally important that clinicians, scientists, and patients are aware of rhabdomyolysis as a potential side effect of vaccination. Suspected vaccine-related ADRs should be promptly and accurately reported via VAERS or other surveillance systems to support the ongoing effort to ensure vaccine safety.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272487/pdf/10.1177_87551225221093944.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9457793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of On-Treatment Viral Loads During Treatment With Direct-Acting Antivirals in Patients Infected With Chronic Viral Hepatitis C.","authors":"Shila Mortazavi,&nbsp;Lauren M Hynicka","doi":"10.1177/87551225221092598","DOIUrl":"https://doi.org/10.1177/87551225221092598","url":null,"abstract":"<p><p><b>Background:</b> Direct-acting antiviral (DAA) agents have revolutionized the treatment of chronic hepatitis C virus (HCV) infection. Current data regarding the utility of on-treatment HCV viral load (VL) monitoring are conflicting and limited data are available in HIV-coinfected patients. <b>Objective:</b> The objective of the study was to determine whether on-treatment VLs are predictive of HCV cure in a real-world population. <b>Method:</b> A single-center, retrospective cohort study was conducted using patients who received a prescription for DAA therapy for HCV treatment at a large, tertiary ambulatory care clinic. <b>Results:</b> A total of 219 patients were included in the final analysis. The average age was 56 years. Most patients were male (64.4%), African American (73.1%), and insured by Medicaid (61.6%). Most patients were treatment-naive, noncirrhotic, and infected with HCV genotype 1a (73.1%). About 22.4% of patients were coinfected with HIV. The most common regimen was 12 weeks of ledipasvir/sofosbuvir (53.9%). On-treatment VLs were most commonly obtained at treatment week 4 (42.5%), of which 45.2% of patients were detectable. Sustained virologic response (SVR) was achieved in 96.8% of the total population and 95.9% of HIV-coinfected patients. Of the 7 patients who did not achieve SVR, 3 patients had undetectable on-treatment VLs in the first 8 weeks of therapy. <b>Conclusion:</b> Sustained virologic response rates were similar between HCV-monoinfected patients and HCV-HIV-coinfected patients. This research further supports that on-treatment VLs may not be a valuable indicator of treatment failure but may be helpful to engage patients in care and ensure treatment adherence and ultimately cure.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272490/pdf/10.1177_87551225221092598.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9560772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Retrospective Analysis of q12hr and q8hr Heparin for DVT/PE Prophylaxis in an Inpatient Rehabilitation Setting.","authors":"Adam Dashner,&nbsp;Erin Siders PharmD","doi":"10.1177/87551225221094171","DOIUrl":"https://doi.org/10.1177/87551225221094171","url":null,"abstract":"<p><p><b>Purpose:</b> There is little clinical evidence comparing the safety and efficacy of prophylactic subcutaneous heparin given every 8 hours and every 12 hours. We performed a retrospective analysis incorporating these dosing intervals in an inpatient rehabilitation setting. <b>Methods</b>: Heparin usage data was collected and patient charts were analyzed for both therapeutic failure and bleeding events. A 2-tailed Fisher's exact test was performed for both outcomes, with a <i>P</i>-value of less than 0.05 being considered significant. Odds ratios were also calculated with <i>P</i>-values less than 0.05 being considered significant. <b>Study Population</b>: A Cerner report was run to identify patients ordered prophylactic heparin in an inpatient rehabilitation setting from April 7, 2020, to October 27, 2021. One hundred patients receiving heparin every 8 hours and every 12 hours were randomly selected for chart review. These study groups were further stratified by Padua risk scores. <b>Results</b>: In both groups, 4 (4.0%) patients were identified as having a documented bleeding event and 2 (2.0%) patients from each group were identified as having a therapy failure. <b>Conclusion</b>: For both endpoints, no significant differences in bleeding rates or therapy failure rates were detected in any of the population stratifications.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272488/pdf/10.1177_87551225221094171.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9439403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health Care Providers' Attitude and Satisfaction Toward Patient-Oriented Services Provided by Pharmacy Technicians at Three Faith-Based Hospitals.","authors":"Suh Nsutebu Ntani,&nbsp;Ngong Ferdinand Tchue","doi":"10.1177/87551225221097038","DOIUrl":"https://doi.org/10.1177/87551225221097038","url":null,"abstract":"<p><strong>Background: </strong>Pharmacists and pharmacy technicians often work together to provide optimal pharmacy services, however, some low-middle-income countries lack strong regulatory mechanisms and have an inadequate number of pharmacists, necessitating some hospitals to rely on pharmacy technicians providing direct patient care services.</p><p><strong>Objectives: </strong>This study sort to investigate health care providers' attitudes and satisfaction toward patient-oriented pharmacy services offered by pharmacy technicians at 3 faith-based hospitals in Cameroon.</p><p><strong>Methods: </strong>A cross-sectional study was conducted from February to April 2021. Self-administered questionnaires were distributed to 159 health care providers (HCPs) in 3 institutions of the Cameroon Baptist Convention Health Services. The questionnaire was made up of 3 parts evaluating HCPs' attitudes and satisfaction.</p><p><strong>Results: </strong>A total of 140 questionnaires were completed (88.1%) response rate. The majority of respondents were female (70%) and <35 years (60.7%). Almost all respondents showed a positive attitude toward pharmacy technicians' role in patient education (90%) and provision of medication information (93.6%). However, only 46% agreed that pharmacy technicians should take medication histories. The majority of respondents were satisfied with overall pharmacy services (80.7%). Only 25% were satisfied with pharmacy technicians' participation in ward rounds. Gender was associated with attitude of respondents (<i>P</i> = 0.02). Factors associated with satisfaction of respondents included profession (<i>P</i> = 0.047) and work experience (<i>P</i> = 0.008).</p><p><strong>Conclusions: </strong>Our results revealed a positive attitude and overall satisfaction with technician-led patient-oriented pharmacy services. Additional training, clear job descriptions, and direct pharmacist supervision could ensure the quality and safety of these services.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272496/pdf/10.1177_87551225221097038.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9591090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurotoxicity Secondary to Valacyclovir.","authors":"Abaigeal E Tarpey,&nbsp;Austin Loranger,&nbsp;Robert Plambeck,&nbsp;Mark A Malesker","doi":"10.1177/87551225221098878","DOIUrl":"https://doi.org/10.1177/87551225221098878","url":null,"abstract":"","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272495/pdf/10.1177_87551225221098878.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9584265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Pharmacogenetics of Opiates and Its Impact on Delirium in Mechanically Ventilated Adults: A Pilot Study.","authors":"C Adrian Austin,&nbsp;Andy Szeto,&nbsp;Apoorva Gupta,&nbsp;Timothy Wiltshire,&nbsp;Daniel J Crona,&nbsp;Christine Kistler","doi":"10.1177/87551225221085116","DOIUrl":"https://doi.org/10.1177/87551225221085116","url":null,"abstract":"<p><p><b>Background:</b> Pharmacogenetics may explain a substantial proportion of the variation seen in the efficacy and risk profile of analgesosedative drugs and the incidence of delirium in critically ill adults. <b>Objectives:</b> Conduct a feasibility study to demonstrate the reliability of collecting and analyzing pharmacogenetic information from critically ill patients and to assess the impact of pharmacogenetics on intensive care unit (ICU) outcomes. <b>Methods:</b> We prospectively enrolled subjects from the Medical ICU at the University of North Carolina (UNC). DNA was obtained via a buccal swab and evaluated using the DNA2Rx assay. We collected data on demographics, daily cumulative psychoactive medication exposure, and severity of illness. We performed daily delirium assessments via the CAM-ICU. We analyzed associations between select single nucleotide polymorphisms (SNPs) and delirium. <b>Results:</b> From June, 2018 through January, 2019, we screened 244 patients and enrolled 50. The median age was 62.0 years old (range: 28-82 years old), and 27 (54%) of the subjects were female. In all, 49 (98%) samples were both high quality and sufficient quantity. In secondary analyses, we found that 80% (12/15) of patients with two 2 copies of a G allele at rs4680 on COMT experienced delirium, whereas 44% (4/9) of patients with 2 copies of an A allele at this location had delirium. In all, 44% (4/9) of patients with 2 T allele copies at rs7439366 on UGT2B7 experienced delirium compared to 73% (11/15) of patients with 2 C allele copies at this location. <b>Conclusions:</b> We can feasibly collect genetic information from critically ill adults. We were able to efficiently collect high quality DNA of sufficient quantity to conduct pharmacogenetic analysis in this critically ill population. Although the sample size of our current study is too small to conduct robust inferential analyses, it suggests potential SNP targets for a future larger study.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272493/pdf/10.1177_87551225221085116.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9665009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}